Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423556 | 0.86 | PDE10A (0.62) | CYSLTR1PDE10ACYSLTR2GPBAR1LGALS3 | |
| SCHEMBL1423807 | 0.86 | PDE10A (0.62) | CYSLTR1PDE10ACYSLTR2GPBAR1 | |
| SCHEMBL1423524 | 0.84 | PDE10A (0.62) | CYSLTR1PDE10ACYSLTR2LGALS3PDE4D | |
| SCHEMBL1424315 | 0.84 | PDE10A (0.62) | CYSLTR1PDE10ACYSLTR2LGALS3PDE4D | |
| SCHEMBL1423591 | 0.84 | CYSLTR1 (0.67) | CYSLTR1PDE10ACYSLTR2GPBAR1 | |
| SCHEMBL1423710 | 0.83 | CYSLTR1 (0.56) | CYSLTR1PDE10ACYSLTR2GPBAR1ALOX5AP | |
| SCHEMBL8649874 | 0.81 | CYSLTR1 (0.63) | CYSLTR1PDE10ACYSLTR2GPBAR1 | |
| SCHEMBL1423590 | 0.80 | PDE10A (0.62) | CYSLTR1PDE10ACYSLTR2GPBAR1LGALS3 | |
| SCHEMBL6583310 | 0.79 | CYSLTR1 (0.78) | CYSLTR1PDE10ACYSLTR2GPBAR1ALOX5AP | |
| SCHEMBL1423674 | 0.79 | PDE10A (0.71) | CYSLTR1PDE10ACYSLTR2LGALS3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2297131-A2 | DI-SUBSTITUTED PHENYL COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Envivo Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009158467-A2 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | PDE10A, PDE1A, PDE12 | CYSLTR1 4596/4885PDE10A 1/4885CYSLTR2 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.